Research ExplorerPublicationsPresence of Circulating Tumor Cells in High-Risk Early Breas...

Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis

Standard

Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. / Trapp, Elisabeth; Janni, Wolfgang; Schindlbeck, Christian; Jückstock, Julia; Andergassen, Ulrich; de Gregorio, Amelie; Alunni-Fabbroni, Marianna; Tzschaschel, Marie; Polasik, Arkadius; Koch, Julian G; Friedl, Thomas W P; Fasching, Peter A; Haeberle, Lothar; Fehm, Tanja; Schneeweiss, Andreas; Beckmann, Matthias W; Pantel, Klaus; Mueller, Volkmar; Rack, Brigitte; Scholz, Christoph; SUCCESS Study Group.

In: JNCI-J NATL CANCER I, Vol. 111, No. 4, 01.04.2019, p. 380-387.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Trapp, E, Janni, W, Schindlbeck, C, Jückstock, J, Andergassen, U, de Gregorio, A, Alunni-Fabbroni, M, Tzschaschel, M, Polasik, A, Koch, JG, Friedl, TWP, Fasching, PA, Haeberle, L, Fehm, T, Schneeweiss, A, Beckmann, MW, Pantel, K, Mueller, V, Rack, B, Scholz, C & SUCCESS Study Group 2019, 'Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis', JNCI-J NATL CANCER I, vol. 111, no. 4, pp. 380-387. https://doi.org/10.1093/jnci/djy152

APA

Trapp, E., Janni, W., Schindlbeck, C., Jückstock, J., Andergassen, U., de Gregorio, A., Alunni-Fabbroni, M., Tzschaschel, M., Polasik, A., Koch, J. G., Friedl, T. W. P., Fasching, P. A., Haeberle, L., Fehm, T., Schneeweiss, A., Beckmann, M. W., Pantel, K., Mueller, V., Rack, B., ... SUCCESS Study Group (2019). Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. JNCI-J NATL CANCER I, 111(4), 380-387. https://doi.org/10.1093/jnci/djy152

Vancouver

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A et al. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. JNCI-J NATL CANCER I. 2019 Apr 1;111(4):380-387. https://doi.org/10.1093/jnci/djy152

Bibtex

@article{f94a62736f434162ae2adc9ce0400007,
title = "Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis",
abstract = "Background: The prognostic relevance of circulating tumor cells (CTCs) at the time of primary diagnosis has been well established. However, little information is available regarding their prognostic relevance to follow-up care.Methods: The multicenter, open-label, phase III SUCCESS A trial compared two adjuvant chemotherapy regimens followed by 2 vs 5 years of zoledronate for early-stage, high-risk breast cancer patients. The presence of CTCs was assessed before and 2 years after chemotherapy using the FDA-approved CellSearch System. Overall survival (OS) and disease-free survival (DFS) were analyzed using univariate log-rank tests and multivariable Cox regressions. OS and DFS were measured starting from an assessment of CTCs 2 years after the completion of chemotherapy. All statistical tests were two-sided.Results: The sample included 1087 patients who participated in the translational research program of the SUCCESS A trial and for whom sufficient translational data were available regarding CTC status at baseline and at the 2-year follow-up visit. Two years after chemotherapy, 198 (18.2%) patients were CTC-positive. The median follow-up after this timepoint was 37 months. Cox regressions that included CTC status at baseline revealed that CTC status 2 years after chemotherapy had statistically significant and independent prognostic relevance for OS (hazard ratio [HR] = 3.91, 95% confidence interval [CI] = 2.04 to 7.52, P < .001) and DFS (HR = 2.31, 95% CI = 1.50 to 3.55, P < .001).Conclusion: The presence of CTCs 2 years after chemotherapy was associated with decreased OS and DFS. Based on these results, active individualized surveillance strategies for breast cancer survivors based on biomarkers should be reconsidered.",
keywords = "Journal Article",
author = "Elisabeth Trapp and Wolfgang Janni and Christian Schindlbeck and Julia J{\"u}ckstock and Ulrich Andergassen and {de Gregorio}, Amelie and Marianna Alunni-Fabbroni and Marie Tzschaschel and Arkadius Polasik and Koch, {Julian G} and Friedl, {Thomas W P} and Fasching, {Peter A} and Lothar Haeberle and Tanja Fehm and Andreas Schneeweiss and Beckmann, {Matthias W} and Klaus Pantel and Volkmar Mueller and Brigitte Rack and Christoph Scholz and {SUCCESS Study Group}",
note = "{\textcopyright} The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2019",
month = apr,
day = "1",
doi = "10.1093/jnci/djy152",
language = "English",
volume = "111",
pages = "380--387",
journal = "JNCI-J NATL CANCER I",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis

AU - Trapp, Elisabeth

AU - Janni, Wolfgang

AU - Schindlbeck, Christian

AU - Jückstock, Julia

AU - Andergassen, Ulrich

AU - de Gregorio, Amelie

AU - Alunni-Fabbroni, Marianna

AU - Tzschaschel, Marie

AU - Polasik, Arkadius

AU - Koch, Julian G

AU - Friedl, Thomas W P

AU - Fasching, Peter A

AU - Haeberle, Lothar

AU - Fehm, Tanja

AU - Schneeweiss, Andreas

AU - Beckmann, Matthias W

AU - Pantel, Klaus

AU - Mueller, Volkmar

AU - Rack, Brigitte

AU - Scholz, Christoph

AU - SUCCESS Study Group

N1 - © The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: The prognostic relevance of circulating tumor cells (CTCs) at the time of primary diagnosis has been well established. However, little information is available regarding their prognostic relevance to follow-up care.Methods: The multicenter, open-label, phase III SUCCESS A trial compared two adjuvant chemotherapy regimens followed by 2 vs 5 years of zoledronate for early-stage, high-risk breast cancer patients. The presence of CTCs was assessed before and 2 years after chemotherapy using the FDA-approved CellSearch System. Overall survival (OS) and disease-free survival (DFS) were analyzed using univariate log-rank tests and multivariable Cox regressions. OS and DFS were measured starting from an assessment of CTCs 2 years after the completion of chemotherapy. All statistical tests were two-sided.Results: The sample included 1087 patients who participated in the translational research program of the SUCCESS A trial and for whom sufficient translational data were available regarding CTC status at baseline and at the 2-year follow-up visit. Two years after chemotherapy, 198 (18.2%) patients were CTC-positive. The median follow-up after this timepoint was 37 months. Cox regressions that included CTC status at baseline revealed that CTC status 2 years after chemotherapy had statistically significant and independent prognostic relevance for OS (hazard ratio [HR] = 3.91, 95% confidence interval [CI] = 2.04 to 7.52, P < .001) and DFS (HR = 2.31, 95% CI = 1.50 to 3.55, P < .001).Conclusion: The presence of CTCs 2 years after chemotherapy was associated with decreased OS and DFS. Based on these results, active individualized surveillance strategies for breast cancer survivors based on biomarkers should be reconsidered.

AB - Background: The prognostic relevance of circulating tumor cells (CTCs) at the time of primary diagnosis has been well established. However, little information is available regarding their prognostic relevance to follow-up care.Methods: The multicenter, open-label, phase III SUCCESS A trial compared two adjuvant chemotherapy regimens followed by 2 vs 5 years of zoledronate for early-stage, high-risk breast cancer patients. The presence of CTCs was assessed before and 2 years after chemotherapy using the FDA-approved CellSearch System. Overall survival (OS) and disease-free survival (DFS) were analyzed using univariate log-rank tests and multivariable Cox regressions. OS and DFS were measured starting from an assessment of CTCs 2 years after the completion of chemotherapy. All statistical tests were two-sided.Results: The sample included 1087 patients who participated in the translational research program of the SUCCESS A trial and for whom sufficient translational data were available regarding CTC status at baseline and at the 2-year follow-up visit. Two years after chemotherapy, 198 (18.2%) patients were CTC-positive. The median follow-up after this timepoint was 37 months. Cox regressions that included CTC status at baseline revealed that CTC status 2 years after chemotherapy had statistically significant and independent prognostic relevance for OS (hazard ratio [HR] = 3.91, 95% confidence interval [CI] = 2.04 to 7.52, P < .001) and DFS (HR = 2.31, 95% CI = 1.50 to 3.55, P < .001).Conclusion: The presence of CTCs 2 years after chemotherapy was associated with decreased OS and DFS. Based on these results, active individualized surveillance strategies for breast cancer survivors based on biomarkers should be reconsidered.

KW - Journal Article

U2 - 10.1093/jnci/djy152

DO - 10.1093/jnci/djy152

M3 - SCORING: Journal article

C2 - 30312434

VL - 111

SP - 380

EP - 387

JO - JNCI-J NATL CANCER I

JF - JNCI-J NATL CANCER I

SN - 0027-8874

IS - 4

ER -